subject: Aarkstore Enterprise - Herpes Simplex - Pipeline Assessment And Market Forecasts To 2017 [print this page] Aarkstore announce a new report "Herpes Simplex - Pipeline Assessment and Market Forecasts to 2017" through its vast collection of market reserach report.
Summary
The industry analysis specialists new report, Herpes Simplex - Pipeline Assessment and Market Forecasts to 2017 is an essential source of information and analysis on the global herpes simplex market. The report identifies the key trends shaping and driving the global herpes simplex market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global herpes simplex sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by industry experts.
Scope
The report provides information on the key driver and challenges of the global herpes simplex market. Its scope includes:
- Annualized global herpes simplex market revenues data from 2001 to 2009, forecast forward for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Key classes of mechanism of action include DNA polymerase inhibitors, Helicase-primase inhibitors, NFkB regulators, HSV-2 gene and nectin-1 receptor targetters, viral maturation inhibitors and PDI inhibitors.
- Analysis of the current and future market competition in the global herpes simplex market. Key market players covered are BioAlliance Pharma, Nutra Pharma Corporation and AiCuris GmbH & Co. KG.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with herpes simplex therapeutics.
